Bio-Techne To Present At The 29th Annual Credit Suisse Virtual Healthcare Conference

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced that CFO Jim Hippel will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 11, 2020, at 4:15 p.m. EST. Interested parties can access the live webcast through the company's Investor Relations website. Bio-Techne specializes in high-quality purified proteins, reagents, and diagnostic products, generating approximately $739 million in net sales in fiscal 2020. With over 2,300 employees, Bio-Techne continues to support scientific research, drug discovery, and clinical diagnostics.

MINNEAPOLIS, Nov. 2, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel, Chief Financial Officer, will present at the 29^th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, 2020 at 4:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,300 employees worldwide.

Contact:	David Clair, Senior Director, Investor Relations & Corporate Development
	david.clair@bio-techne.com
	612-656-4416

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-29th-annual-credit-suisse-virtual-healthcare-conference-301164639.html

SOURCE Bio-Techne Corporation

FAQ

When will Bio-Techne present at the Credit Suisse Virtual Healthcare Conference?

Bio-Techne will present on November 11, 2020, at 4:15 p.m. EST.

How can I watch Bio-Techne's presentation at the conference?

You can access the live webcast of Bio-Techne's presentation via their Investor Relations website.

What is Bio-Techne's stock symbol?

Bio-Techne's stock symbol is TECH.

What products does Bio-Techne offer?

Bio-Techne offers purified proteins, reagents, diagnostic products, and genomic tools.

What were Bio-Techne's net sales in fiscal 2020?

Bio-Techne generated approximately $739 million in net sales in fiscal 2020.